https://www.selleckchem.com/pr....oducts/Tipifarnib(R1
Serum E6011 concentrations increased dose-dependently after infusion and reached a plateau around 4-6weeks. Serum total FKN rose simultaneously. Five (18%) patients developed anti-E6011 antibodies during the study. Overall, clinical response and clinical remission were observed at Week 12 in 40% (10/25) and 16% (4/25) of active CD patients, respectively. E6011 was well-tolerated and might be effective in CD patients. These findings need to be clarified in a randomized controlled study. E6011 was well-tolerated and might be e
Like
Comment
Share
